Glucocorticoid Therapy in Asthma

  • Joseph D. Spahn
  • Stanley J. Szefler
Part of the Current Clinical Practice book series (CCP)


Glucocorticoid (GC) therapy remains one of the most valuable treatment methods in the management of both the acute and chronic manifestations of asthma. GCs have been used in the treatment of asthma for the past 50 yr. Initial studies evaluating the effect of cortisone on asthma revealed significant improvements in asthma symptoms and pulmonary function. Unfortunately, much of the early enthusiasm for oral GC use was dampened with the realization that long-term use of this medication resulted in multiple adverse effects. The subsequent development of highly effective inhaled GC preparations has revolutionized asthma care. By virtue of high topical to systemic potency, inhaled GC therapy has proven to be safe and effective in the treatment of asthma. This chapter will provide a broad overview of the structure, mechanisms of action, pharmacokinetics, efficacy, adverse effects and current issues associated with GC therapy in asthma.


Fluticasone Propionate Acute Asthma Triamcinolone Acetonide Peak Expiratory Flow Rate Beclomethasone Dipropionate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  1. Agertoft L, Pedersen S. Bone mineral density in children with asthma receiving long-term treatment with budesonide. Am J Respir Crit Care Med 1998; 157: 178–183.PubMedCrossRefGoogle Scholar
  2. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88: 373–381.PubMedCrossRefGoogle Scholar
  3. Donahue JG, Weiss ST, Livingston JM, et al. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997; 277: 887–891.PubMedCrossRefGoogle Scholar
  4. Ernst P, Spitzer WO, Suissa S, et al. Risk of fatal and near fatal asthma in relation to inhaled corticosteroid use. JAMA 1992; 268: 3462–3464.PubMedCrossRefGoogle Scholar
  5. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma National Institutes of Health, National Heart, Lung, and Blood Institute. NIH publication No. 97–4051, 1997.Google Scholar
  6. Fanta CH, Rossing TH, McFadden ER. Glucocorticoids in acute asthma: A critical controlled study. Am J Med 1983; 74: 845–851.PubMedCrossRefGoogle Scholar
  7. Haahtela T, Jarvinen M, Kava T, Kiviranta K, et. al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331: 700–705.PubMedCrossRefGoogle Scholar
  8. Harris JB, Weinberger MM, Nassif E, Smith G, Milavetz G, Stillerman A. Early intervention with short courses of prednisone to prevent progression of asthma in ambulatory patients incompletely responsive to bronchodilators. J Pediatr 1987; 110: 627–633.PubMedCrossRefGoogle Scholar
  9. Harter JG, Reddy WJ, Thorn GW. Studies on an intermittent corticosteroid dosage regimen. N Engl J Med 1963; 269: 591–596.PubMedCrossRefGoogle Scholar
  10. McFadden ER Jr. Dosages of corticosteroids in asthma Am Rev Respir Dis 1993; 147: 1306–1310.PubMedCrossRefGoogle Scholar
  11. Robinson D, Hamid Q, Ying S, Bentley A, Assoufi B, Durham, Kay AB. Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-y cytokine gene expression. Am Rev Respir Dis 1993; 148: 401–406.PubMedCrossRefGoogle Scholar
  12. Simons FER, and the Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. A comparison of beclomethasone dipropionate, salmeterol, and placebo in children with asthma. N Engl J Med 1997; 337: 1659–1665.CrossRefGoogle Scholar
  13. Toogood JH, Baskerville JC, Markov AE, et al. Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma J Allergy Clin Immunol 1995; 96: 157–166.PubMedCrossRefGoogle Scholar
  14. Toogood JH, Baskerville J, Jennings B, Lefcoe NM, Johansson S-A. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol 1989; 84: 688–700.PubMedCrossRefGoogle Scholar
  15. Webb JR. Dose response of patients to oral corticosteroid treatment during exacerbations of asthma. Br J Med 1986; 292: 1045–1047.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Joseph D. Spahn
  • Stanley J. Szefler

There are no affiliations available

Personalised recommendations